QUEST DIAGNOSTICS INC(DGX)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
QUEST DIAGNOSTICS INC (DGX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DGX at 69.0/100 on a 32-signal composite quality model, placing it at rank #287 of 2,961 stocks — the top 10% of the AI-ranked universe. DGX scores in the top quartile across revenue scale (87.7), earnings quality (81.3), balance sheet strength (75.0). Based on the latest XBRL financial filings (Q2 2026), QUEST DIAGNOSTICS INC reports quarterly revenue of $3.0B, net income of $320.0M, an operating margin of 15.1%. Top institutional holders of DGX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. DGX trades on the NYSE exchange and files with the SEC under CIK 1022079. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for QUEST DIAGNOSTICS INC directly from SEC EDGAR.
AI Quality Score
69.0/100
AI Rank
#287
Revenue
$3.0B
Net Income
$320.0M
Free Cash Flow
$459.0M
Operating Margin
15.1%
DGX key financials by period
QUEST DIAGNOSTICS INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$11.0B
$992.0M
14.1%
FY 2024
10-K
$9.9B
$871.0M
13.6%
FY 2023
10-K
$9.3B
$854.0M
13.6%
FY 2022
10-K
$9.9B
$946.0M
14.4%
FY 2021
10-K
$10.8B
$2.0B
22.1%
FY 2020
10-K
$9.4B
$1.4B
20.9%
Institutions holding DGX
Institutional investors reporting a position in QUEST DIAGNOSTICS INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-23 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net revenues rose 10.2% to $3,043M as DIS requisition volume jumped 13.1%, while revenue per requisition fell 2.8% on Corewell Health and Fresenius routine-test mix.
Biggest Revenue Drivers
Diagnostic Information Services (DIS)$2,978M+10.3% YoY
Principally driven by organic growth of 10.1%; volume up 13.1% with ~9 points from Corewell Health and Fresenius Medical Care testing
Diagnostic Solutions (DS)$65M+4.3% YoY
Principally consistent with the prior year period
Biggest Revenue Drivers
Total revenue: $3,043M+10.2% YoY
Diagnostic Information Services (DIS)$2,978M+10.3% YoY
Principally driven by organic growth of 10.1%; volume up 13.1% with ~9 points from Corewell Health and Fresenius Medical Care testing
Diagnostic Solutions (DS)$65M+4.3% YoY
Principally consistent with the prior year period
Largest Expense Items
Cost of services$2,016M+10.9% YoY
Higher compensation costs and increased supplies expense reflecting higher testing volumes, partially offset by Invigorate cost savings
Selling, general and administrative$529M+9.0% YoY
Primarily driven by higher compensation costs
Amortization of intangible assets$38M-4.4% YoY
Principally consistent with the prior year period
Margins: Operating income was $459M, or 15.1% of net revenues versus 15.9% a year ago; cost of services rose to 66.3% of revenues from 65.8%, as compensation and supplies outpaced Invigorate savings.
Watch Items from the Filing
Revenue per requisition fell 2.8%, driven by Corewell Health and Fresenius Medical Care mix, which includes a greater proportion of routine tests; excluding them it rose about 3%.
Roughly 9 of the 13.1% DIS volume growth came from two relationships — Corewell Health and Fresenius dialysis clinics; underlying organic volume grew about 4%.
Payer mix shifted: healthcare insurers fell to 37% of net revenues from 40%, while client payers rose to 32% from 30% and patients to 13% from 12%.
Days sales outstanding rose to 50 days from 48 at December 31, 2025 and 47 a year ago; accounts receivable consumed $259M of operating cash year-to-date.
Reserves for general and professional liability claims totaled $174M, including Ireland pap smear screening claims; legal matter reserves were $17M with AMCA data-incident class actions ongoing.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
